Back to results
US 6,156,303 AGranted
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
AssigneeUniversity of Washington
InventorsDavid W. Russell, Elizabeth A. Rutledge
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Washington
InventorsDavid W. Russell, Elizabeth A. Rutledge
Estimating the term…
The present invention provides isolated adenovirus-associated viruses ("AAV"), including AAV isolates designated AAV3B and AAV6. The invention also provides nucleic acid molecules of AAV3B (SEQ ID NO: 1) or AAV6 (SEQ ID NO: 2), including DNA or RNA, and provides substantially purified polypeptides encoded by AAV3B or AAV6, as well as antibodies specific for such polypeptides. The invention also provides infectious AAV3B and AAV6 clones; AAV viral vectors, which can be hybrid AAV viral vectors; AAV vector plasmids; and AAV helper plasmids; each comprising at least a portion of an AAV3B (SEQ ID NO: 1) or AAV6 (SEQ ID NO: 2) nucleic acid molecule. The invention further provides host cells containing at least a portion of an AAV3B or AAV6 nucleic acid molecule and progeny cells derived therefrom, and provides non-human transgenic mammals having an AAV vector genome stably integrated in a chromosome. The invention also provides methods of producing a polypeptide or an RNA by expressing the polypeptide or the RNA from an AAV viral vector in a cell, and methods of treating a pathologic condition in a mammal, comprising transducing cells of the mammal with an AAV viral vector containing a heterologous nucleic acid sequence. The invention also provides AAV3B or AAV6 nucleotide sequences, which can be useful, for example, as probes for identifying the presence of AAV3B or AAV6 nucleic acids in a sample. The present invention further provides a method of identifying an AAV viral vector suitable for administration to an individual.
An isolated adeno-associated virus serotype 6 (AAV6) comprising a genomic nucleic acid sequence as shown in SEQ ID NO:
A substantially purified nucleic acid molecule, comprising the nucleotide sequence of SEQ ID NO:
An infectious AAV6 clone, comprising a substantially purified double stranded nucleic acid molecule comprising an unique portion of the nucleotide sequence of SEQ ID NO:
An AAV vector genome, comprising a functional portion of a nucleotide sequence of SEQ ID NO:
An AAV plasmid, comprising a functional portion of a nucleotide sequence of SEQ ID NO:
An AAV viral vector, comprising at least a peptide portion of an AAV6 polypeptide, provided said portion is not a portion of an AAV2 polypeptide or an AAV3A polypeptide.
A nucleotide sequence, comprising at least nine unique contiguous nucleotides of SEQ ID NO:
A method of introducing a heterologous nucleic acid sequence into a mammalian cell, comprising contacting the mammalian cell with an AAV viral vector, comprising an AAV6 vector genome containing at least an unique portion of the nucleotide sequence of SEQ ID NO:2 and containing the heterologous nucleic acid sequence or an AAV viral vector comprising a heterologous nucleic acid and comprising a functional portion of an unique AAV6 polypeptide, under conditions which allow transduction of said mammalian cell, thereby introducing a vector genome containing a heterologous nucleic acid sequence into said mammalian cell.
Dependencies are inferred from the claim text.